Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds for the treatment of life threatening, drug-resistant infectious disease. Pravibismane is the first in this new class of anti-infective drugs with a novel mechanism of action and broad-spectrum potency against multi-drug resistant bacteria/superbugs, resistant fungal pathogens, and bacterial biofilms. Pravibismane targets specialty markets with high unmet medical need representing over ~$4B in peak annual sales potential for pravibismane in the U.S. Inhaled pravibismane is in preclinical development for the treatment of CF/NTM lung infections. Topical pravibismane is in Ph. 2 development for treatment of diabetic foot infections. Pravibismane’s potential has been validated through ~$27M in non-dilutive grants awarded to-date from the U.S. NIH, U.S. Army, U.S. Navy, CARB-X, and the Cystic Fibrosis Foundation, and FDA Fast Track, QIDP and Orphan Drug designations.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):